Ovid Therapeutics and Takeda announced the co-development of soticlestat, and Ovid Therapeutics is now listed on the Nasdaq exchange.
1 report, 1 independent
Updated Sep 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ovid Therapeutics and Takeda announced the co-development of soticlestat, and Ovid Therapeutics is now listed on the Nasdaq exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Ovid Therapeutics stock traded on the Nasdaq exchange on July 18, 2026.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Praxis Precision Medicines listed its shares on the Nasdaq stock exchange on July 17, 2026.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.